Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 19 April 2023
Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)Product type:GuidanceProgramme:Highly specialised technologies guidanceLast updated: 19 April 2023Published: 7 July 2021